The Efficacy and Safety of a Combination Therapy of Rosuvastatin and Ezetimibe Versus Monotherapy of Rosuvastatin in Hypercholesterolemia Patients
NCT ID: NCT02251847
Last Updated: 2014-09-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
400 participants
INTERVENTIONAL
2014-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase III Study of Rosuvastatin and Fenofibrate Versus Rosuvastatin in Mixed Dyslipidemia
NCT02262143
The Efficacy and Safety of Combination Therapy of Rosuvastatin and Ezetimibe and Rosuvastatin Monotherapy in Patients With Primary Hypercholesterolemia
NCT03288038
Efficacy and Safety of Combination of Rosuvastatin and Ezetimibe in Patients With Primary Hypercholesterolemia
NCT03571087
A Clinical Trial to Compare the Efficacy and Safety of a Combination Therapy of Ezetimibe and Rosuvastatin Versus Monotherapy of Rosuvastatin in Hypercholesterolemia Patients (I-ROSETTE Study)
NCT02749994
A Study to Compare Rosuvastatin/Ezetimibe and Rosuvastatin in Patients With Diabetes Mellitus and Hypercholesterolemia
NCT03217409
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
R5
Rosuvastatin 5mg
Rosuvastatin/Ezetimibe
Rosuvastatin 5mg
R10
Rosuvastatin 10mg
Rosuvastatin/Ezetimibe
Rosuvastatin 5mg
R20
Rosuvastatin 20mg
Rosuvastatin/Ezetimibe
Rosuvastatin 5mg
R5/E10
Rosuvastatin 5mg/ezetimibe 10mg
Rosuvastatin/Ezetimibe
Rosuvastatin 5mg
R10/E10
Rosuvastatin 10mg/ezetimibe 10mg
Rosuvastatin/Ezetimibe
Rosuvastatin 5mg
R20/E10
Rosuvastatin 20mg/ezetimibe 10mg
Rosuvastatin/Ezetimibe
Rosuvastatin 5mg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rosuvastatin/Ezetimibe
Rosuvastatin 5mg
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
19 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
IlDong Pharmaceutical Co Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tae Hoon Ahn
Role: PRINCIPAL_INVESTIGATOR
Gachon University Gil Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Gil Medical Center
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Tae Hoon Ahn
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ID-ROEZ-301
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.